Качественное офтальмологическое оборудование для профессионалов!
Тел.: +7 495 662 7866

Ellex

2RT FOR EARLY AMD: THE ROLE OF NANOSECOND LASER TECHNOLOGY


Ellex invites you to join us in Vienna to learn about the role of 2RT® as an intervention for early AMD. Hosted as part of the EuroTimes Satellite Education Program, this lunchtime symposium will be your opportunity to be among the first to hear the latest clinical data for 2RT®.

DATE: Saturday, 22 September
TIME: 1:00 – 2:00pm
VENUE: Congress Center
MODERATOR: Prof. Usha Chakravarthy

FACULTY:
Usha Chakravarthy, MD, PhD  (Ireland)
Robyn Guymer MB, BS, PhD, FRANZCO (Australia)
John Marshall PhD, FRCPath, FRCOphth (Hon) (UK)
Robert Finger, MD, PhD (Germany)

Retinal Rejuvenation Therapy, 2RT®, stimulates a biological healing process that results in cellular rejuvenation, renewing the entire transport mechanism of the retina and improving the hydraulic conductivity of Bruch’s membrane. This rejuvenation process preserves or improves functional vision and reduces disease progression — without causing collateral damage to the overlying photoreceptor rods and cones of the retina. 2RT® offers the potential to intervene earlier in the treatment of AMD before significant vision loss has occurred to slow or halt the degeneration process.

Ellex is the manufacturer of 2RT®. It has been approved for the indications Clinically Significant Macular Edema (CSME) and in patients with early Age-Related Macular Degeneration (AMD) where it can produce bilateral improvements in macular appearance and function under CE marking. Ellex does not accept any responsibility for use of the system outside of these indications. The material presented herein may include the views or recommendations of third parties and does not necessarily reflect the views of Ellex Medical Pty Ltd.

2RT® has a CE Mark (Conformité Européenne) for treatment in patients with early AMD where it can produce bilateral improvements in macular appearance and function.

2RT® has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) (510k) Market release for the treatment of Clinically Significant Macula Edema (CSME).